However, emerging preclinical and limited clinical research has explored potential indirect relationships between GLP-1 signalling and the HPA axis
The truth is that, currently, DSIP is still on the FDAs Category 2 list of restricted drugs as of September 2024.30 So the only way to get a proper pharmaceutical-grade version is to qualify for an exemption from the Federal Food, Drug, and Cosmetic Act, which requires that you:31 Have a prescription from a licensed clinician Need the specified medication (i.e., no other treatment on the market can safely or effectively treat your health condition) Going through a clinic that specializes in these kinds of treatments may help fast-track your way to an exemption, presuming youre a suitable candidate
Insulin can help transport L-Carnitine into muscle cells more effectively
[4] Conditions that match a drugs FDA approval generally qualify, whether youre using these major GLP-1 brands or similar: Ozempic/Mounjaro: type 2 diabetes [5] Wegovy/Zepbound: obesity (BMI 30) [6] Wegovy/Zepbound: overweight with at least one weight-related condition (BMI 27 to under 30 plus hypertension, high cholesterol, sleep apnea, cardiovascular disease, or type 2 diabetes) [7] Zepbound: obstructive sleep apnea [8] Wegovy: metabolic-associated steatohepatitis (MASH) [9] Off-label conditions can count too when your clinician documents a real diagnosis such as prediabetes, binge eating disorder, or PCOS
Havent lost much weight but stay tuned
